BPC-157 and Liver Function: What Women Need to Know Before Using This Peptide

What Is BPC-157 and Why Are Women Asking About It?

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide sequence derived from a protein found in human gastric juice. Researchers have studied it in animal models for tissue repair in tendons, ligaments, the gut lining, and the central nervous system. The liver angle has attracted attention because BPC-157 appears to influence nitric oxide signaling, cytoprotective pathways, and growth factor expression in ways that animal data suggest may reduce hepatocellular injury.

Women are encountering BPC-157 on social media, in functional medicine clinics, and through 503A compounding pharmacies that can legally prepare it for individual patients with a prescription. The compound sits in a regulatory gray zone. It is not FDA-approved for any indication, but compounding pharmacies may prepare it for specific patients under a valid prescription. The FDA has flagged BPC-157 as a substance that raises significant safety concerns when used outside of an IND, and enforcement has increased since 2023.

The liver interest is not arbitrary. Women carry specific liver-disease burdens that differ from men in meaningful ways. Metabolic-associated steatotic liver disease (MASLD, formerly NAFLD) affects roughly one in three women with PCOS, and perimenopausal estrogen decline accelerates hepatic fat accumulation. Understanding whether BPC-157's preclinical liver signals could ever translate to clinical use requires first understanding the actual evidence, its limits, and what it could mean specifically for you.

The Peptide's Mechanism at the Liver: Animal Data Only

In rodent models, BPC-157 appears to act through several overlapping pathways relevant to hepatic protection.

Nitric oxide modulation. BPC-157 stabilizes the nitric oxide (NO) system, preventing both NO over-production and under-production. Hepatic injury from acetaminophen, alcohol, and ischemia-reperfusion involves NO dysregulation. Animal studies show BPC-157 attenuates this dysregulation in liver tissue.

Cytoprotection via growth factor signaling. The peptide upregulates expression of EGF receptor and VEGFR2 in injured tissue, including gut and hepatic tissue. This may accelerate restoration of the mucosal and hepatocellular barrier.

Counteraction of drug-induced hepatotoxicity. In the Sikiric et al. 2018 review in the Journal of Physiology and Pharmacology, the authors summarized data showing BPC-157 reversed liver damage caused by NSAIDs, alcohol, and chemotherapy agents in rat and mouse models. Liver enzyme normalization (ALT, AST) was observed within days in several of those experiments.

None of these mechanisms have been confirmed in human liver tissue. The translation from rat hepatocyte to human hepatocyte is not guaranteed, and sex-specific hepatic pharmacology in women is almost entirely unstudied for this compound.

The Evidence Gap Is Real and Larger Than Most Sources Admit

Here is a framework for thinking about what we actually know versus what is being claimed about BPC-157 and liver function. Four tiers of evidence apply:

| Evidence Tier | Status for BPC-157 Liver Claims | |---|---| | Tier 1: Human RCT with liver endpoints | Not completed | | Tier 2: Human observational or case series data | Single case reports only; not peer-reviewed for liver | | Tier 3: Non-human primate or large mammal data | Absent for liver endpoints | | Tier 4: Rodent/in vitro data | Extensive, consistent, but species-limited |

Every claim you read about BPC-157 "protecting the liver" is operating at Tier 4. That matters for your clinical decision-making. Women have been historically underrepresented in early-phase peptide and regenerative medicine trials, and BPC-157 is no exception. There is no dataset stratified by sex, hormonal status, or reproductive stage for any BPC-157 endpoint, including liver outcomes.

The Sikiric 2018 paper is the most-cited primary source for BPC-157 liver effects. It is a comprehensive animal-model review from a Croatian research group that has studied BPC-157 for over two decades. The science is methodologically careful within its domain. The gap is not the quality of the animal work. The gap is the complete absence of bridging studies in humans.

How Sex-Specific Liver Physiology Changes the Picture

Women's livers are not simply smaller versions of men's livers. Hepatic drug metabolism, fat distribution, and inflammation patterns differ by sex and shift across the reproductive lifespan.

Estrogen and Hepatic Fat Regulation

Estrogen receptors are abundant in hepatocytes. Estradiol promotes fatty acid oxidation and reduces de novo lipogenesis, which is one reason premenopausal women have lower rates of MASLD than age-matched men. After menopause, when estradiol falls, hepatic fat accumulation accelerates and MASLD prevalence in women surpasses that of men in the same age cohort. Any future BPC-157 liver trial that does not stratify by menopausal status will produce results that are difficult to interpret for women specifically.

PCOS and Fatty Liver

Polycystic ovary syndrome affects an estimated 8 to 13 percent of reproductive-age women worldwide. Women with PCOS have insulin resistance, androgen excess, and frequently elevated liver enzymes even in the absence of obesity. MASLD prevalence in PCOS cohorts reaches 35 to 70 percent depending on the diagnostic criteria used, according to a 2021 meta-analysis in the Journal of Clinical Endocrinology and Metabolism. Because BPC-157 has shown effects on insulin signaling pathways in animal models, it has attracted attention in the PCOS community. There is no clinical trial data to support its use in PCOS-related fatty liver. Drawing a line from rodent insulin data to a PCOS liver benefit in a human woman is premature.

Hormonal Contraception and Hepatic Metabolism

Women using combined hormonal contraceptives experience changes in hepatic protein synthesis, coagulation factor production, and drug metabolism via CYP3A4 and CYP2C9. BPC-157's interactions with these enzyme pathways have not been studied. If future trials establish hepatic effects, researchers will need to account for OCP use as a major covariate in female subjects.

Postmenopausal Metabolic Shifts

After menopause, visceral fat redistributes toward the abdomen, insulin sensitivity declines, and hepatic inflammation markers rise. Postmenopausal women on hormone therapy show partial reversal of these trends, as documented in the WHI observational extension data. Any peptide compound being considered in this population would need to be evaluated against the backdrop of concurrent hormone therapy, which changes the hepatic milieu substantially.

What Animal Studies Actually Show About BPC-157 and Liver Injury

Acetaminophen-Induced Hepatotoxicity Models

Multiple rodent experiments from the Sikiric group show that BPC-157 at doses of 10 mcg/kg body weight significantly reduced ALT and AST elevations after acetaminophen overdose compared to vehicle-treated controls. Histologically, the peptide-treated animals showed less centrilobular necrosis. The proposed mechanism involves upregulation of glutathione synthesis and stabilization of hepatocyte mitochondrial membranes.

Alcohol-Induced Liver Injury Models

In chronic alcohol-exposure models, BPC-157 reduced hepatic steatosis scores and lowered serum ALT in treated rats. This is biologically plausible given the compound's effects on mucosal integrity and NO stabilization, since alcohol-related liver disease involves gut-liver axis disruption alongside direct hepatocellular toxicity.

NSAID-Hepatotoxicity and the Gut-Liver Axis Connection

BPC-157 was originally characterized as a gastric cytoprotective compound. Its protective effects on the gastric mucosa may secondarily reduce liver injury by limiting NSAID-driven gut permeability and endotoxin translocation. This gut-liver axis mechanism is distinct from direct hepatoprotection and may actually be the more relevant pathway if the peptide ever demonstrates human efficacy.

Chemotherapy-Related Hepatotoxicity

Animal data shows BPC-157 attenuated liver enzyme elevations induced by the chemotherapy agent cyclophosphamide in rodent models. For women undergoing breast cancer treatment, chemotherapy-related hepatotoxicity is a real clinical problem. This finding generates a research question worth pursuing in human trials, particularly given breast cancer's female predominance. No such trial exists.

Dosing, Administration, and Pharmacokinetics in Women: What Is Not Known

Compounding pharmacies preparing BPC-157 in the United States typically supply it for subcutaneous injection or oral capsule use. Animal studies predominantly use intraperitoneal administration, which does not translate directly to subcutaneous or oral bioavailability in humans.

Oral bioavailability for peptides of this size is generally low due to proteolytic degradation in the stomach and intestine. The gastric origin of BPC-157 is sometimes used to argue that it resists degradation and has higher oral bioavailability than typical peptides, but no published human pharmacokinetic study confirms oral plasma concentrations in women or men.

Sex-based pharmacokinetic differences in peptide absorption and clearance are documented for other therapeutic peptides. Women tend to have lower renal clearance rates per kilogram of body weight and different body composition affecting volume of distribution. BPC-157 dosing protocols currently circulating in compounding literature are not weight-adjusted for these sex differences. Until pharmacokinetic studies in women exist, any dose is genuinely a guess.

Pregnancy, Lactation, and Contraception: Mandatory Safety Section

BPC-157 should not be used during pregnancy or lactation. This is a firm clinical position based on the complete absence of human gestational safety data, not a precautionary overstatement.

Pregnancy

No animal teratogenicity studies with BPC-157 have been published in peer-reviewed literature as of mid-2025. The compound has no FDA pregnancy category because it has never been reviewed for an NDA or BLA. When no teratogenicity data exists, the responsible clinical default is avoidance during pregnancy. BPC-157 influences growth factor signaling pathways (EGF, VEGF, bFGF) that are actively involved in placentation, trophoblast invasion, and fetal organogenesis. Perturbation of these pathways during embryonic development carries theoretical teratogenic risk that cannot be dismissed without data.

If you become pregnant while using BPC-157, discontinue it immediately and inform your obstetric provider.

Lactation

Peptide transfer into breast milk depends on molecular size, lipophilicity, and active transport mechanisms. BPC-157 is a 15-amino-acid peptide with a molecular weight of approximately 1,419 Da. Peptides of this size may transfer into milk, and infant exposure through nursing would be unpredictable. No lactation transfer data exists for BPC-157 in any species. Breastfeeding women should not use BPC-157.

Contraception

Because the effects on early pregnancy are unknown, women of reproductive age using BPC-157 should use reliable contraception. The compound should be discontinued at least one full menstrual cycle before attempting conception to allow clearance, though the actual elimination half-life in humans is unstudied.

Who This May Be Relevant For and Who Should Avoid It

Potentially Relevant (Research Context Only, No Clinical Recommendation)

• Women with PCOS-related MASLD interested in emerging research directions
• Perimenopausal women with metabolic liver changes who want to follow peptide research
• Women recovering from NSAID overuse who have mild transaminase elevations and are curious about adjunctive approaches currently under investigation

In every case above, the appropriate action is monitoring the published literature, not using the compound, until human trials establish safety and efficacy in women.

Who Should Avoid BPC-157 Entirely

• Pregnant women or those actively trying to conceive
• Breastfeeding women
• Women with established liver disease of any cause (cirrhosis, autoimmune hepatitis, primary biliary cholangitis), given completely unknown interactions
• Women with a personal or family history of hormone-sensitive cancers, given BPC-157's growth factor signaling activity and absent oncological safety data
• Women using immunosuppressants, anticoagulants, or oncology drugs, where peptide interactions are unknown

Monitoring and What to Ask Your Clinician

If your provider has prescribed BPC-157 via a compounding pharmacy and you choose to proceed, ask for baseline liver function tests including ALT, AST, alkaline phosphatase, GGT, and total bilirubin before starting. Repeat at four weeks and twelve weeks. If ALT or AST rises above three times the upper limit of normal, the compound should be discontinued and a hepatology consult considered.

"There is no clinical threshold established for peptide-related transaminase elevations because no human safety trial has defined one," according to the FDA's general guidance on drug-induced liver injury signals in IND applications. Any transaminase rise on an unproven compound warrants taking it seriously.

Track your menstrual cycle while using any compounded peptide. Cycle irregularities can be the first sign of hormonal disruption and provide a practical clinical signal that something is affecting your endocrine system.

The Regulatory Field and What May Change

BPC-157 occupies an unstable regulatory position. In 2023 and 2024, the FDA took action against multiple compounding pharmacies preparing BPC-157, characterizing it as a bulk drug substance that has not been evaluated for safety or effectiveness and that presents potential risks. The FDA's bulk drug substance list does not include BPC-157 as an approved nominee.

A Phase I human safety trial would be the minimum bar needed to establish any basis for clinical use. As of the date of this article, no completed registered Phase I trial for BPC-157 with liver endpoints appears in ClinicalTrials.gov. One registered trial from a European investigator group was listed as recruiting in 2023 for musculoskeletal endpoints, not liver outcomes.

The women's health research community has separately called for sex-stratified design in all peptide trials. The NIH policy requiring sex as a biological variable in NIH-funded preclinical and clinical research applies to future BPC-157 studies. Enforcement of this policy would mean any future human trial must include women and analyze results by hormonal status.

Practical Bottom Line for Women Considering BPC-157 for Liver Health

The animal data on BPC-157 and liver function is genuinely interesting. Consistent hepatoprotective signals across multiple injury models, plausible mechanisms, and a long research track record from one productive group make BPC-157 a compound worth watching. The problem is that "worth watching" and "worth taking" are entirely different positions.

Your liver's biology is not the same as a male rat's, and it changes substantially depending on whether you are cycling, pregnant, postpartum, perimenopausal, or postmenopausal. The compound has never been studied in a human woman's liver. The dose you would receive from a compounding pharmacy is not based on female pharmacokinetic data. The long-term safety profile is unknown for anyone, and the pregnancy and lactation risks are genuinely unstudied.

If you have PCOS-related fatty liver, perimenopausal metabolic changes, or a history of drug-induced transaminase elevations, the evidence-based steps available right now are weight management, addressing insulin resistance through metformin or GLP-1 receptor agonists where indicated, reducing alcohol, and treating the underlying hormonal drivers of your liver disease. Your ALT responds to those interventions in ways that are documented in women by named trials. BPC-157 does not yet meet that bar.

Ask your provider about joining a research registry or watching for early-phase trial enrollment if you want to contribute to the evidence base. That is the right role for an interested woman right now, not self-prescribing an unvalidated compound based on rodent hepatocyte data.